Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus EOHILIA.
DEXACORT vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category C
Category C
Corticosteroid
Corticosteroid